MK-2214 / Merck (MSD)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-2214 / Merck (MSD)
MK-2214-002, NCT05466422: A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease

Recruiting
1
48
US
MK-2214, Placebo
Merck Sharp & Dohme LLC
Alzheimer Disease
05/25
05/25

Download Options